乌司他丁治疗不同类型急性胰腺炎的临床疗效  

Clinical Efficacy of Ulinastatin in the Treatment of Different Types of Acute Pancreatitis

作　　者：荣媛[1] 刘明华[1] 邓朝霞[1] 王娟[1] 尹昌林[1] 李晓萍[1] 

机构地区：[1]解放军第三军医大学西南医院急救部,重庆400038

出　　处：《现代生物医学进展》2015年第14期2696-2699,共4页Progress in Modern Biomedicine

基　　金：国家自然科学基金项目(30972894)

摘　　要：目的:探讨乌司他丁用于治疗不同类型急性胰腺炎的临床疗效和安全性。方法:收集2013年1月至2014年1月我院收治的急性胰腺炎患者84例,随机分为观察组与对照组,每组各42例,两组患者均给予常规治疗,对照组加用奥曲肽治疗,观察组在对照组的基础上加用乌司他丁治疗,观察和比较两组患者的临床疗效、治疗前后血清IL-6和TNF-α水平的变化及不良反应的发生情况。结果:观察组的总有效率为96.72%,显著高于对照组的85.71%;其中,两组急性水肿型胰腺炎的疗效相当(P<0.05),但观察组出血坏死型胰腺炎的有效率显著高于对照组(P<0.05)。治疗后,两组血清IL-6与TNF-α水平均较治疗前显著降低,并且观察组显著低于对照组(P<0.05),水肿型胰腺炎患者血清IL-6及TNF-α水平显著低于出血坏死型胰腺炎患者,差异均具有统计学意义(P<0.05)。两组均未发生肝肾功能损害,未见药物相关性不良反应。结论:乌司他丁用于辅助治疗急性胰腺炎能够明显下调炎症因子水平,临床疗效显著,对急性水肿型胰腺炎的疗效尤为显著,安全性好,值得推广应用。Objective： To. investigate the clinical efficacy and safety of ulinastatin in treatment of different types of acute pancreatitis. Methods： 84 cases of patients with acute pancreatitis admitted in our hospital from January 2013 to January 2014 were selected and randomly divided into the observation group and control group. Both groups received conventional treatment, the control group received octreotide treatment, observation group received ulinastatin on the basis of the control group, the clinical efficacy, serum IL-6 and TNF-α levels before and after treatment, the occurrence of adverse reactions of two groups were compared. Results： The total effective rate of observation group was 96.72%, which was significantly higher than that of the control group （85.71%）; no significant difference was found in the efficacy of acute edematous pancreatitis （AEP） betwen the two groups （P〈0.05）, but the efficiency of acute hemorrhagic necrotizing pancreatitis （AHNP） in the observation group was significantly higher than that of the control group（P〈0.05）. After treatment, the serum IL-6 and TNF-α levels of both groups were significantly lower than those before treatment （P〈0.05）, and the serum IL-6 and TNF-α levels of observation group were significantly lower than those of the control group （P〈0.05）, the serum IL-6 and TNF-α levels of patients with AEP were significantly lower than those with AHNP （P〈0.05）. There was no significant difference or drug-related adverse reactions in the liver and kidney dysfunction between two groups. Conclusions： Ulinastatin could significantly lower the levels of inflammatory factors in the treatment of AEP and AHNP and had significant clinical effect on the AEP, it should be widely applied in clinic.

关 键 词：急性胰腺炎 乌司他丁 水肿型胰腺炎 出血坏死型胰腺炎 临床疗效 

分 类 号：R576[医药卫生—消化系统]